Drugs / TCR-MAGE-A4 T-Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06170294 | Jan 2024 → Dec 2025 overdue | neoplasm | Peking University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR-MAGE-A4 T-Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06170294 ↗ |
| Modality | Cell therapy | “T cell receptor-engineered T cell (TCR-T)” NCT06170294 ↗ |